Navigation Links
AMDL Inc.'s JJB Plant Receives Production Approval From Chinese State Food and Drug Administration (SFDA)
Date:5/8/2009

TUSTIN, Calif., May 8 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its JJB wholly foreign-owned subsidiary located in Shangrao, Jiangxi Province, China has received approval from the Chinese State Food and Drug Administration (SFDA) to re-initiate product production on its small injectable manufacturing line which is specifically used to produce the Goodnak(R) anti-aging injectable product and other small volume parenteral solutions.

The SFDA requires all China-based companies engaged in the manufacture of pharmaceutical products to have "Good Manufacturing Practices" (GMP) certification. In Q108, JJB's GMP certification expired and the Company initiated $1.5 million in plant renovations to bring the facility and its operations into compliance with the SFDA. With today's announcement, JJB has reopened the Jiangxi-based plant and resumed operations for its small injectable manufacturing line.

According to Mr. Douglas MacLellan, Chairman and CEO of AMDL, "Based on the pending renewal of our GMP-certification for the JJB plant we anticipated a temporary cease in operations at JJB and planned accordingly by successfully amounting adequate product supply to meet distributor demand through SFDA approval. The manufacturing lines at this facility have resumed operations and we remain on track with our quarterly and fiscal year business and financial projections."

For additional information on AMDL, its FY09 financial forecast, portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at kszarkowitz@amdl.com .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Nanowire coating for bone implants, stents
6. Circulating fats kill transplanted pancreas cells, study shows
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Implantable device designed to detect, stop seizures under study at MCG
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. Bone-growing nanomaterial could improve orthopaedic implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... ... The quest to develop a cure for HIV has long been plagued by ... has a knack for lying dormant in immune cells at levels undetectable to all ... Graduate School of Public Health announced today in Nature Medicine that they’ve created a ...
(Date:5/28/2017)... Melbourne, FL (PRWEB) , ... May 28, 2017 ... ... Partners of America (PPOA), is proud to announce that Jorge Fernandez-Silva, M.D., has ... comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques to ...
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article ... for colds or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions ... may be largely responsible for the problem both in Canada and the United States. ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals ... event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... network of independent hearing healthcare providers to help them stay ahead in the industry. ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease Association’s ... eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be ... The American Parkinson Disease Association (APDA) is focused on advancing scientific research that ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
Breaking Medicine Technology: